| 영문 | VDRL(venereal disease research laboratory) | 한글 | 성병 연구실험실 |
|---|---|---|---|
| 설명 | 매독균의 reagin에 대한 항체. 매독의 선별검사로 사용되며 매독 치료에 대한 반응 여부와 치료효과 판정에도 사용된다. 매독외에도 전신성홍반성낭창, 류마티스관절염 등에서도 양성으로 나타날 수 있다. |
||
| 영문 | Dilatation and Curettage(D & C) | 한글 | 자궁긁어냄술, 자궁목확장 |
|---|---|---|---|
| 설명 | 자궁이란 태아가 수태되어서 분만전까지 발육하고 성장하는 공간이다. 자궁속에 병변이 있어 임신이 계속될 수 없거나 아니면 다른 이유로 임신되어 있는 태아를 제거하고자 할 경우에 사용되는 방법이다. 여기서 긁어내기 위하여는 우선 자궁의 입구에 해당하는 자궁목을 확장시켜야 한다. 여기에는 급속히 확장을 시도하는 법과 서서히 확장을 시도하는 2가지 방법이 있다. 자궁목을 급속히 확장할 때는 헤가르 목관확장기(Hegar's dilatator)를 사용한다. 이것은 작은 금속막대로 작은 크기부터 큰 크기까지 다양한 크기가 있어서 우선 작은 막대로 시작하여 점점 큰 크기의 막대를 자궁목에 넣어서 자궁목을 확장시킨다. 서서히 확장시킬 때는 Laminaria tent를 목관에 삽입하는 방법을 사용한다. Laminaria tent란 해초로 만든 작은 막대로 수분을 흡수하면 점점 늘어나는 성질이 있다. 이것을 자궁의 목에 넣으면 이것이 수분을 흡수하여 늘어나므로 천천히 자궁의 목이 늘어난다. 자궁목이 충분히 늘어나면 그 속으로 끝이 숟가락처럼 생긴 기구를 넣어서 자궁속의 병변이나 임신된 태아를 긁어내는데 여기에 사용되는 숟가락처럼 생긴 기구를 큐렛이라고 한다. 초기 임신중절 즉 유산과 같은 임신과 관련된 경우뿐만 아니라, 비임신 자궁의 자궁내막조직의 채취 및 제거를 위해서도 행해지는 수기이다. 이는 원칙적으로 마취하에 실시되는 것으로 자궁목관을 확장하고 기구로 자궁 내용물을 제거하고 큐렛으로 자궁내벽을 깨끗이 한다. 자궁천공이나 자궁목의 파열 등의 위험이 따르며, 수술후 감염 또는 출혈 등에 대한 주의가 필요하다. |
||
| ECG | Electro-Cardio-Graphy(-Gram); 심전도 = EKG 1. Conducting System Structu... |
|---|---|
| BPS | beats per second; Behavioral Pharmacological Society; biophysical profile score; bits per second; bo... |
| C2 | second cervical nerve; second cervical vertebra; second component of complement |
| DDP | cisplatin; density-dependent phosphoprotein; difficult denture patient; digital data processing; dis... |
| LAP | laparoscopy; laparotomy; left arterial pressure; left atrial pressure; leucine aminopeptidase; leuke... |
| DPP | Dentin phosphoprotein |
|---|---|
| P | Phosphoprotein |
| pp | Phosphoprotein |
| VASP | Vasodilator-Stimulated Phosphoprotein |
| mRNA | E-messenger RNA |
| second messenger | <molecular biology> In many hormone sensitive systems the systemic hormone does not enter the target cell but binds to a receptor and indirectly affects the production of another molecule within the cell, this diffuses intracellularly to the target enzymes or intracellular receptor to produce the response. This intracellular mediator is called the second messenger. Examples include cyclic AMP, cyclic GMP, IP3 and diacylglycerol. (18 Nov 1997) |
|---|---|
| second messenger systems | Systems in which an intracellular signal is generated in response to an intercellular primary messenger such as a hormone or neurotransmitter. They are intermediate signals in cellular processes such as metabolism, secretion, contraction, phototransduction, and cell growth. Examples of second messenger systems are the adenyl cyclase-cyclic AMP system, the phosphatidylinositol diphosphate-inositol triphosphate system, and the cyclic GMP system. (12 Dec 1998) |
| vasodilator stimulated phosphoprotein | <protein> A 46/50 kD protein that is a substrate for both cAMP and cGMP dependent protein kinases and that is associated with microfilament bundles in many tissue cells. Abundant in platelets, phosphorylation of VASP will inhibit platelet activation. (18 Nov 1997) |
| phosphoprotein | <protein> Proteins that contain phosphate groups esterified to serine, threonine or tyrosine (s, T or Y). The phosphate group usually regulates protein function. (18 Nov 1997) |
| phosphoprotein phosphatase | <enzyme> A group of enzymes removing the serine- or threonine-bound phosphate groups from a wide range of phosphoproteins, including a number of enzymes which have been phosphorylated under the action of a kinase. (enzyme nomenclature, 1992) Chemical name: Phosphoprotein phosphohydrolase Registry number: EC 3.1.3.16 (12 Dec 1998) |
| united states agency for health care policy and research | An agency of the public health service established in 1990 to "provide indexing, abstracting, translating, publishing, and other services leading to a more effective and timely dissemination of information on research, demonstration projects, and evaluations with respect to health care to public and private entities and individuals engaged in the improvement of health care delivery.." it supersedes the national centre for health services research. (12 Dec 1998) |
| masked messenger RNA | <molecular biology> Long lived and stable mRNA found originally in the oocytes of echinoderms and constituting a store of maternal information for protein synthesis that is unmasked (derepressed) during the early stages of morphogenesis. In these early stages the rate of cell division is so rapid that transcription from the embryonic genome cannot occur. Undoubtedly not restricted to oocytes and the term can be applied to any mRNA which is present in inactive form. (18 Nov 1997) |
| messenger | 1. That which carries a message. 2. Having message-carrying properties. First messenger, a hormone that binds to a receptor on the surface cell and, in so doing, communicates with intracellular metabolic processes. Second messenger, an intermediary molecule that is generated as a consequence of hormone-receptor interaction; e.g., see adenosine 3',5'-cyclic monophosphate; guanosine 3',5'-cyclic monophosphate; calcium; inositide. (05 Mar 2000) |
| messenger-like RNA | An ill-defined form of RNA, of high molecular weight, that never leaves the nucleus and is thought to be the precursor of messenger RNA. (05 Mar 2000) |
| messenger RNA | <molecular biology> Single stranded RNA molecule that specifies the amino acid sequence of one or more polypeptide chains. This information is translated during protein synthesis when ribosomes bind to the mRNA. In prokaryotes, mRNA is normally formed by splicing a large primary transcript from a DNA sequence and protein synthesis starts while the mRNA is still being synthesised. Prokaryote mRNAs are usually very short lived (average t 1/2 is 5mins.). In contrast, in eukaryotes the primary transcripts (HnRNA) are synthesised in the nucleus and they are extensively processed to give the mRNA that is exported to the cytoplasm where protein synthesis takes place. This processing includes the addition of a 5' 5' linked 7 methyl guanylate cap at the 5' end and a sequence of adenylate groups at the 3' end, the poly A tail, as well as the removal of any introns and the splicing together of exons, only 10% of HnRNA leaves the nucleus. Eukaryote mRNAs are comparatively long lived with a half life ranging from 30minutes to 24 hours. (27 Jun 1999) |
| Venereal Disease Research Laboratory | <microbiology> A blood test used to diagnose syphilis. Read as nonreactive or negative if you do not have syphilis. The Venereal Disease Research Laboratory can also be positive is cases of leprosy, malaria, mononucleosis, lupus, hepatitis A and pregnancy. Positive Venereal Disease Research Laboratory tests are usually followed up by a more specific test (FTA antibodies). (12 Jan 1998) |
| Medical Research Council | <organisation> A UK Government funded body to promote the balanced development of medical and related biological research in the United Kingdom. It organises national clinical trials for the assessment of new treatment protocols for leukaemia and some of the related diseases. (05 Jan 1998) |
| research | Careful, a diligent search, a close searching, studious inquiry or examination. (18 Nov 1997) |
| research, controlled | The first controlled clinical research was probably done in 1875 by the british naval surgeon james lind who, on board the hms salisbury, gave sailors with scurvy either oranges or lemons or cider or vinegar or nutmeg (or another treatment) and after just six days discovered that the citrus-consuming sailors had recovered from scury, until then the scourge of extended sea voyages, while the sailors who had been given the other treatments remained uncured. (12 Dec 1998) |
| research design | A plan for collecting and utilizing data so that desired information can be obtained with sufficient precision or so that an hypothesis can be tested properly. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|